Marion Wealth Management Acquires 167 Shares of Johnson & Johnson (NYSE:JNJ)

Marion Wealth Management grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.4% during the fourth quarter, HoldingsChannel reports. The firm owned 1,626 shares of the company’s stock after purchasing an additional 167 shares during the quarter. Marion Wealth Management’s holdings in Johnson & Johnson were worth $235,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Seven Mile Advisory grew its holdings in shares of Johnson & Johnson by 1.8% during the second quarter. Seven Mile Advisory now owns 4,841 shares of the company’s stock valued at $708,000 after buying an additional 84 shares during the last quarter. Wilkins Investment Counsel Inc. lifted its holdings in Johnson & Johnson by 5.6% in the second quarter. Wilkins Investment Counsel Inc. now owns 127,842 shares of the company’s stock valued at $18,685,000 after acquiring an additional 6,768 shares during the period. Rock Point Advisors LLC grew its position in Johnson & Johnson by 1.2% during the second quarter. Rock Point Advisors LLC now owns 6,103 shares of the company’s stock valued at $892,000 after buying an additional 70 shares during the period. Providence Wealth Advisors LLC increased its stake in shares of Johnson & Johnson by 3.2% in the 2nd quarter. Providence Wealth Advisors LLC now owns 9,440 shares of the company’s stock worth $1,390,000 after purchasing an additional 293 shares in the last quarter. Finally, Stevard LLC raised its stake in shares of Johnson & Johnson by 2.7% in the second quarter. Stevard LLC now owns 3,820 shares of the company’s stock worth $558,000 after buying an additional 100 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.7 %

Shares of NYSE:JNJ opened at $144.50 on Tuesday. The company has a market capitalization of $347.90 billion, a price-to-earnings ratio of 20.91, a PEG ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The business has a 50-day moving average price of $149.39 and a 200 day moving average price of $156.10. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the business earned $2.66 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wells Fargo & Company upped their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Guggenheim raised their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Bank of America reiterated a “neutral” rating and set a $166.00 price target on shares of Johnson & Johnson in a report on Tuesday, December 10th. Royal Bank of Canada lifted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Finally, Wolfe Research began coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.71.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.